Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the United States, Europe, and Canada. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis (PBC). In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist, a second dedicated bile acid receptor that has completed a Phase 1 clinical trial; and INT-777, an orally administered TGR5 agonist, which completed preclinical studies for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China. The company was founded in 2002 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ICPT
CUSIP45845P10
Phone646-747-1000
Debt
Debt-to-Equity Ratio-6.88
Current Ratio4.58
Quick Ratio4.58
Price-To-Earnings
Trailing P/E Ratio-5.92
Forward P/E Ratio-7.45
P/E GrowthN/A
Sales & Book Value
Annual Sales$130.96 million
Price / Sales19.23
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book130.95
Profitability
EPS (Most Recent Fiscal Year)($14.38)
Net Income$-360,360,000.00
Net Margins-241.33%
Return on Equity-573.64%
Return on Assets-68.54%
Miscellaneous
Employees507
Outstanding Shares29,580,000
Intercept Pharmaceuticals (NASDAQ:ICPT) Frequently Asked Questions
What is Intercept Pharmaceuticals' stock symbol?
Intercept Pharmaceuticals trades on the NASDAQ under the ticker symbol "ICPT."
How were Intercept Pharmaceuticals' earnings last quarter?
Intercept Pharmaceuticals Inc (NASDAQ:ICPT) issued its quarterly earnings results on Tuesday, May, 8th. The biopharmaceutical company reported ($3.22) EPS for the quarter, beating analysts' consensus estimates of ($3.41) by $0.19. The biopharmaceutical company had revenue of $35.96 million for the quarter, compared to analysts' expectations of $38.44 million. Intercept Pharmaceuticals had a negative net margin of 241.33% and a negative return on equity of 573.64%. The business's quarterly revenue was up 70.9% on a year-over-year basis. During the same period last year, the business earned ($3.61) earnings per share. View Intercept Pharmaceuticals' Earnings History.
What price target have analysts set for ICPT?
21 Wall Street analysts have issued twelve-month price targets for Intercept Pharmaceuticals' shares. Their forecasts range from $50.00 to $253.00. On average, they expect Intercept Pharmaceuticals' stock price to reach $124.4737 in the next twelve months. View Analyst Ratings for Intercept Pharmaceuticals.
What are Wall Street analysts saying about Intercept Pharmaceuticals stock?
Here are some recent quotes from research analysts about Intercept Pharmaceuticals stock:
- 1. Cantor Fitzgerald analysts commented, "PBC – Despite headwinds associated with labeling harmonization for Ocaliva and widened gross-to-net impact expected for the earlier portion of the year, scripts for the drug have been reported to have stabilized. We believe efforts towards educating and creating confidence for prescribing physicians may have stemmed the tide and signal the return to revenue growth. While our long-term projections remain conservative (20% at peak), continued execution in the remainder of 2018 could build our confidence and expand opportunity for the shares. That said, we remain cautious on NASH." (5/8/2018)
- 2. According to Zacks Investment Research, "Intercept’s fourth-quarter results missed expectations as sales of Ocaliva declined due to safety issues surrounding the drug. The approval of Ocaliva was a significant boost for Intercept. However, prescription demand has softened following the Dear Health Care Provider letter and the FDA safety communication on Ocaliva. The company also announced an updated label for Ocaliva in the United States, reinforcing appropriate dosing in PBC patients with Child-P Class B or C or decompensated cirrhosis. While the updated label should help the stock turn around, it might be a while before the sales start to recover. First-quarter is expected to be a transitional quarter. Meanwhile, Intercept is evaluating Ocaliva for other indications including NASH and PSC. Given the challenges faced by the drug in recent times, the label expansion of OCA will boost the growth prospects. Shares have underperformed the industry in the last six months." (2/19/2018)
- 3. Needham & Company LLC analysts commented, "Intercept reported $40.9M in WW 3Q17 Ocaliva sales, with $4.1M attributed to one-time accounting adjustment. Excluding adjustment, WW and U.S. Ocaliva sales were $36.8M and $32.5M, respectively, both in-line with our and consensus $36M and $33M ests. Company has completed safety review w/ independent committee and discussions w/ FDA are underway. Changes to U.S. label are expected by early 1Q18. Safety concerns appear to have had modest impact on NRX since FDA letter and we have reduced our ests accordingly. Long-term sales in PBC may be negatively impacted by large number of competing programs in development. Maintain HOLD." (11/1/2017)
- 4. Wells Fargo & Co analysts commented, "an increased risk of serious liver injury and death." The letter resulted in a 25 percent selloff in Intercept's stock on Thursday, and some Wall Street analyst's felt it prudent to take action.Wells Fargo's Jim Birchenough downgraded Intercept's stock rating from Overweight to Market Perform with a price target slashed from $265 all the way down to $95 as the letter goes beyond a previous warning.The FDA's letter contains new pieces of information that weren't included in the prior "Dear Healthcare Provider Letter," the analyst highlighted. For example, 19 separate deaths have been identified since Ocaliva's launch in May 2016. The cause of death was worsening primary biliary cholangitis in seven of these cases, cardiovascular disease in one case, with the other cases being unknown.Among the eight cases with a known cause of death, seven of the patients received an incorrect dose, Birchenough continued. In addition, the FDA highlighted 11 cases of serious liver injury, of which six patients were given an incorrect dose resulting in three of the 19 deaths."We believe that serious events in patients with mild or no baseline liver disease, treated with correct doses of OCALIVA, and the recommendation for increased monitoring could dramatically impact OCALIVA adoption in PBC, and introduces a potential overhang on the development for non alcoholic steatohepatitis (NASH), with phase 3 data not expected until early 2019 and potential increased risk of imbalance in serious adverse events (SAE's)," (9/21/2017)
Who are some of Intercept Pharmaceuticals' key competitors?
Some companies that are related to Intercept Pharmaceuticals include Nektar Therapeutics (NKTR), Sarepta Therapeutics (SRPT), Genmab A/S (GNMSF), BeiGene (BGNE), Valeant Pharmaceuticals Intl (VRX), Alkermes (ALKS), SAGE Therapeutics (SAGE), Dr.Reddy's Laboratories (RDY), Catalent (CTLT), Agios Pharmaceuticals (AGIO), Ionis Pharmaceuticals (IONS), Loxo Oncology (LOXO), FibroGen (FGEN), United Therapeutics (UTHR) and GALAPAGOS NV/S (GLPG).
Who are Intercept Pharmaceuticals' key executives?
Intercept Pharmaceuticals' management team includes the folowing people:
- Dr. Mark Pruzanski, Founder, CEO, Pres & Director (Age 50)
- Mr. Sandip S. Kapadia, CFO, Treasurer & Principal Accounting Officer (Age 48)
- Dr. David Shapiro M.D., Ph.D., Chief Medical Officer (Age 64)
- Ms. Lisa Bright B.Sc., Pres of International (Age 50)
- Mr. Jerome B. Durso, Chief Operating Officer (Age 50)
Has Intercept Pharmaceuticals been receiving favorable news coverage?
News headlines about ICPT stock have trended somewhat positive on Thursday, according to Accern. The research group scores the sentiment of media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Intercept Pharmaceuticals earned a media sentiment score of 0.03 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 46.17 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
Who are Intercept Pharmaceuticals' major shareholders?
Intercept Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include GENEXTRA S.P.A. (23.30%), Senvest Management LLC (3.89%), BB Biotech AG (1.84%), Altrinsic Global Advisors LLC (1.27%), Elk Creek Partners LLC (1.18%) and Melqart Asset Management UK Ltd (1.01%). Company insiders that own Intercept Pharmaceuticals stock include Barbara Gayle Duncan, Daniel G Welch, David Shapiro, Francesco Micheli, Keith Michael Gottesdiener, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Institutional Ownership Trends for Intercept Pharmaceuticals.
Which institutional investors are selling Intercept Pharmaceuticals stock?
ICPT stock was sold by a variety of institutional investors in the last quarter, including Spark Investment Management LLC, A.R.T. Advisors LLC, Guggenheim Capital LLC, Pinnacle Associates Ltd., LPL Financial LLC, BNP Paribas Arbitrage SA, Teacher Retirement System of Texas and State Board of Administration of Florida Retirement System. Company insiders that have sold Intercept Pharmaceuticals company stock in the last year include Daniel G Welch, David Shapiro, Lisa Bright, Mark Pruzanski, Rachel Mcminn, Richard J Kim and Sandip Kapadia. View Insider Buying and Selling for Intercept Pharmaceuticals.
Which institutional investors are buying Intercept Pharmaceuticals stock?
ICPT stock was acquired by a variety of institutional investors in the last quarter, including Elk Creek Partners LLC, Point72 Asset Management L.P., Senvest Management LLC, Millennium Management LLC, Melqart Asset Management UK Ltd, Scopia Capital Management LP, Altrinsic Global Advisors LLC and BB Biotech AG. Company insiders that have bought Intercept Pharmaceuticals stock in the last two years include Francesco Micheli, Keith Michael Gottesdiener and Mark Pruzanski. View Insider Buying and Selling for Intercept Pharmaceuticals.
How do I buy shares of Intercept Pharmaceuticals?
Shares of ICPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intercept Pharmaceuticals' stock price today?
One share of ICPT stock can currently be purchased for approximately $85.12.
How big of a company is Intercept Pharmaceuticals?
Intercept Pharmaceuticals has a market capitalization of $2.51 billion and generates $130.96 million in revenue each year. The biopharmaceutical company earns $-360,360,000.00 in net income (profit) each year or ($14.38) on an earnings per share basis. Intercept Pharmaceuticals employs 507 workers across the globe.
How can I contact Intercept Pharmaceuticals?
Intercept Pharmaceuticals' mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company can be reached via phone at 646-747-1000 or via email at [email protected]
MarketBeat Community Rating for Intercept Pharmaceuticals (ICPT)
MarketBeat's community ratings are surveys of what our community members think about Intercept Pharmaceuticals and other stocks. Vote "Outperform" if you believe ICPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ICPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
